Definitive Healthcare CORP

Definitive Healthcare Corp. has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Definitive Healthcare Corp. and SE VII DHC AIV, L.P. (Spectrum) have terminated their Nominating Agreement, ending Spectrum's right to designate a board nominee.

Definitive Healthcare Corp. announced fourth quarter and full year 2025 financial results, with Q4 revenue exceeding guidance despite a year-over-year decrease.

Definitive Healthcare reported Q3 2025 financial results, with revenue at the high end of guidance and Adjusted EBITDA exceeding expectations, despite a year-over-year revenue decrease.

Definitive Healthcare reported second-quarter revenue of $60.8 million, exceeding guidance, and raised its full-year 2025 revenue and adjusted EBITDA outlook despite year-over-year declines in key financial metrics.

Definitive Healthcare Corp. reports the resignation of Jill Larsen from its Board of Directors and Compensation Committee, leading to a reduction in board size and the appointment of Scott Stephenson as the new Compensation Committee Chair.

Definitive Healthcare Corp. reported a decrease in revenue for the first quarter of 2026, citing sales execution challenges and macroeconomic headwinds, while also recording a significant goodwill impairment charge.

Definitive Healthcare Corp. reported a 4% revenue decline in Q3 2025 and a 5% decline for the nine months, attributing the downturn to macroeconomic pressures and sales execution challenges, despite a reduced net loss.

Definitive Healthcare Corp. reported a net loss for Q2 2025, with revenue declining due to sales execution challenges and macroeconomic headwinds, despite a significantly lower goodwill impairment charge compared to the prior year.

Definitive Healthcare Corp. reported a net loss of $155.1 million for Q1 2025, primarily due to a goodwill impairment charge and a decrease in revenue.

Definitive Healthcare Corp. reported its Q3 2024 results, which included a substantial goodwill impairment charge and a slight decrease in revenue compared to the same period last year.

Definitive Healthcare Corp. reported its second quarter 2024 results, which were significantly impacted by a goodwill impairment charge and restructuring efforts, despite a slight increase in revenue.

Definitive Healthcare Corp. reported a 4% decrease in revenue for fiscal year 2025, alongside substantial goodwill impairment charges and a decline in customer retention, attributing challenges to macroeconomic conditions and sales execution issues.

Definitive Healthcare Corp. releases its 10-K filing for the fiscal year ended December 31, 2024, detailing financial performance, strategic initiatives, and an upcoming CFO transition.

Definitive Healthcare Corp.'s 10-K filing for fiscal year 2023 reveals a net loss of $289.6 million, alongside a detailed overview of its business, risk factors, and financial performance.

Kevin Coop, CEO of Definitive Healthcare Corp., reported a transaction involving the withholding of shares to cover tax obligations.

Definitive Healthcare Corp. Chief Legal Officer Jonathan Paris reported a transaction involving the withholding of shares to cover tax obligations.

Director Samuel A. Hamood acquired 189,190 restricted stock units of Definitive Healthcare Corp. Class A Common Stock.

Definitive Healthcare Corp. director Scott G. Stephenson was granted 189,190 restricted stock units as part of annual compensation.

Definitive Healthcare Corp. director Kathleen A. Winters was granted 189,190 restricted stock units as part of annual equity compensation.

Director Chilukuri Sastry acquired 189,190 shares of Class A Common Stock in Definitive Healthcare Corp. through restricted stock units.

Definitive Healthcare Corp. is holding its 2026 Annual Meeting of Stockholders on June 4, 2026, to elect directors, ratify auditors, and approve an amendment to its equity incentive plan.

Definitive Healthcare Corp. will hold its annual stockholder meeting on June 5, 2025, to elect directors, ratify the appointment of Deloitte & Touche LLP, and approve executive compensation.

Definitive Healthcare Corp. is set to hold its 2025 Annual Meeting of Stockholders on June 5, 2025, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Definitive Healthcare Corp. eliminates the President position, resulting in Jonathan Maack's departure, and appoints Kate Shamsuddin Jensen as Chief Strategy Officer and William Moschella as Chief Product and Technology Officer, effective May 1, 2024.

Definitive Healthcare Corp. will hold its annual meeting of stockholders on May 22, 2024, to vote on director elections, ratification of the company's accounting firm, and executive compensation.

Definitive Healthcare Corp. will hold its 2024 Annual Meeting of Stockholders on May 22, 2024, to vote on director elections, auditor ratification, and executive compensation.

Advent International, L.P. and its affiliates have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Definitive Healthcare Corp. Class A Common Stock as of March 31, 2026.

Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, have reported a 5.7% beneficial ownership stake in Definitive Healthcare Corp. as of December 31, 2025.

Advent International and its affiliated entities have filed an amended Schedule 13G, confirming their beneficial ownership of 54.84% of Definitive Healthcare Corp.'s Class A Common Stock.

Jason Ronald Krantz, a key individual, has filed an Amendment No. 3 to Schedule 13G, disclosing a beneficial ownership of 16.9% of Definitive Healthcare Corp.'s Class A Common Stock as of March 31, 2025.

Irenic Capital Management LP and its affiliates have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Definitive Healthcare Corp.'s Class A Common Stock.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a passive beneficial ownership of 7.7% in Definitive Healthcare Corp.'s common stock as of March 31, 2025.